<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35594160</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1536-5166</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society</Title>
          <ISOAbbreviation>J Neuroophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reply to Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?</ArticleTitle>
        <Pagination>
          <StartPage>e535</StartPage>
          <EndPage>e536</EndPage>
          <MedlinePgn>e535-e536</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/WNO.0000000000001377</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gordon</LastName>
            <ForeName>Lynn K</ForeName>
            <Initials>LK</Initials>
            <AffiliationInfo>
              <Affiliation>Ophthalmology, Stein Eye Institute, UCLA, Los Angeles, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sadun</LastName>
            <ForeName>Alfredo A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Ophthalmology, Doheny Eye Institute, UCLA, Los Angeles, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van Stavern</LastName>
            <ForeName>Greg</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Andrew G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Neuroophthalmol</MedlineTA>
        <NlmUniqueID>9431308</NlmUniqueID>
        <ISSNLinking>1070-8022</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I031V2H011</RegistryNumber>
          <NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013700" MajorTopicYN="Y">Giant Cell Arteritis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35594160</ArticleId>
        <ArticleId IdType="doi">10.1097/WNO.0000000000001377</ArticleId>
        <ArticleId IdType="pii">00041327-202206000-00056</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sadun A, Gordon L. Should tocilizumab be used routinely in new patients with a diagnosis of giant cell arteritis? J Neuroophthalmol. 2020;40:117–121.</Citation>
        </Reference>
        <Reference>
          <Citation>Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–328.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
